COMP <GO>
LQDA vs INDV // 10Y YIELD & FRED MACRO BETA
Liquidia Corporation (NASDAQ) VS. Indivior Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: LQDA 4
— INDV 6
▲ 10Y YIELD & FRED MACRO BETA LEADER: INDV
LAST: $41.85 (-7.12%) • MKT CAP: $4.03B
macro-sensitivity
0.90
LAST: $35.37 (+0.34%) • MKT CAP: $4.17B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LQDA VS. INDV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LQDA | INDV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 80.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.60% | 62.20% | -74.80 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 13.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.99% | -2.24% | +1.25 | LQDA | /fcf-yield <GO> |
| Operating Margin | -32.50% | 21.10% | -53.60 | INDV | /operating-margins <GO> |
| Net Profit Margin | -43.50% | 16.90% | -60.40 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 4.30% | +175.70 | LQDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.33 | 3.13 | +3.20 | LQDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 52.3 | +0.20 | LQDA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.90 | 1.15 | -0.25 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 18.4x | +2.60 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.03B | $4.17B | -$141.6M | INDV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LQDA REV | INDV REV | LQDA GROSS % | INDV GROSS % | LQDA FCF | INDV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $158.3M | $1.24B | — | 80.2% | -$40.0M | -$93.0M |
| FY 2024 | $14.0M | $1.19B | 58.0% | 80.6% | -$98.4M | $7.0M |
| FY 2023 | $17.5M | $1.09B | — | — | -$42.4M | -$349.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LQDA // BETA 0.90
INDV // BETA 1.15